That’s the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent ...

Enanta Pharmaceuticals has initiated legal action against Pfizer (PFE) over a patent infringement related to Paxlovid, ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...

Enanta Pharmaceuticals (NASDAQ:ENTA) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE) and some of ...

Pfizer ($PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported ...

Topline Pfizer said on Monday it will spend $120 million to boost production of its Covid-19 antiviral treatment Paxlovid, as the White House continues its efforts to increase access to the first ...

In that case, Pfizer could make as much as $5.8 billion in a year from Paxlovid. That's roughly in line with the $5.3 billion cost of the supply that the government initially purchased.

In a study designed to test Paxlovid in "standard-risk" adults, Pfizer enrolled more than 1,100 people ages 18 and up. To join the study, they had to be within five days of a positive Covid-19 ...

Paxlovid is not approved, according to Pfizer, but is authorized for emergency use by the FDA to treat mild-to-moderate COVID-19 in high-risk patients age 12 and older, weighing at least 88 pounds ...

Doses of the anti-viral drug Paxlovid are displayed in New York, on Monday, Aug. 1, 2022. Pfizer's COVID-19 pill may provide little benefit for younger adults, while still reducing the risk of ...

Enata Pharmaceuticals is suing Pfizer in a European Union court, alleging Pfizer's Paxlovid Covid-19 antiviral violates one of its patents. Enata said its patent, published Wednesday in the European ...